Business
Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open
Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of its Community Colorectal Cancer Screening Grant Program, designed to support community-led efforts to expand access to colorectal cancer screening throughout March.
About this update from Guardant Health, Inc.
[{"type":"text","content":"Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in March","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"PALO ALTO, Calif., Feb. 12, 2026 /PRNewswire/ -- Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of its Community Colorectal Cancer Screening Grant Program, designed to support community-led efforts to expand access to colorectal cancer screening throughout March.","length":381,"tagName":"p"},{"type":"text","content":"As part of the grant program, Guardant Health will provide selected patient advocacy, non-profit, public health and health-adjacent organizations with up to 100 Shield tests per organization to support efforts to increase screening participation, including community health fairs, screening events and awareness month programming and educational outreach. All Shield tests will be provided at no cost to the patient or participating organization.","length":446,"tagName":"p"},{"type":"text","content":"Shield is the first and only blood test approved by the FDA as a primary screening option for CRC for adults age 45 and older at average risk, offering patients a more pleasant and convenient option for screening by overcoming barriers associated with other screening methods.","length":276,"tagName":"p"},{"type":"text","content":"Colorectal cancer is the leading cause of cancer-related deaths nationwide, yet it is highly preventable through recommended screening. Guardant's grant program reflects the company's commitment to removing barriers to screening – particularly in underserved and underscreened communities – and supporting community partners who are on the front lines of improving access to screening. ","length":393,"tagName":"p"},{"type":"text","content":"Organizations with strong community and health outreach are encouraged to apply. Groups interested in participating should review the Request for Proposals (RFP) and complete the application form available here. Applications are due by February 17, 2026 (midnight PST), and approval notifications will be sent via e-mail on February 20, 2026.","length":342,"tagName":"p"},{"type":"text","content":"For q...